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K e y  M e s s a g e 
A live recombinant Salmonella oral vaccine platform 
against avian influenza viruses was constructed. 
Live recombinant Salmonella oral vaccine against 
avian influenza viruses
Introduction
In 1997, the avian influenza virus (AIV) subtype 
H5N1 was first reported to infect humans.1 Up to 3 
March 2015, the cumulative number of confirmed 
human cases of H5N1 was 784, with 429 deaths. 
There is no evidence that H5N1 viruses can transmit 
efficiently from person to person.2 Therefore, the key 
to prevention of a human H5N1 pandemic is to first 
control the H5N1 virus in birds.
 Traditionally, inactivated influenza vaccines 
have been used prophylactically against pandemic 
influenza. However, their cost is high and yield is 
low, and they are difficult to administer on a large 
scale. The use of live, attenuated Salmonella vaccines 
has been extensively studied. Salmonella is a Gram-
negative, intracellular bacterium.3 It has advantages 
as a live antigen delivery vector.4 First, it can be 
modified to express a wide range of antigens. Second, 
live Salmonella vaccine is easy to administer; it can 
be mixed with food and given to birds orally. Third, 
after oral administration, Salmonella can penetrate 
the Peyer’s patches via M cells in the gastrointestinal 
tract and colonise the mesenteric lymph nodes 
that contain various antigen-presenting cells.3 
This can generate a range of immune responses, 
including mucosal and systemic immunity. Fourth, 
live Salmonella vaccine can be easily and cheaply 
produced.5
  This study constructed analogous sets of live 
recombinant Salmonella Typhimurium vaccine 
strains expressing a model antigen—enhanced 
green fluorescent protein (EGFP). The advantages 
and deleterious or synergistic effects of these 
vaccine strains were identified by comparing their 
immunogenicity in mice.
Methods
To develop an effective, live recombinant Salmonella 
oral vaccine against avian influenza viruses, 
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EGFP was used as a model antigen to study the 
relationship between immunogenicity and different 
antigen expression systems in Salmonella. Six 
‘single-recombinant’ strains were constructed: 
three cytoplasmic expression strains based on a 
high or low copy plasmid, or the chromosome 
expression cassette (HP, LP and CP); two outer-
membrane expression strains developed from a 
high copy plasmid or chromosome (HO, CO); 
and one eukaryotic expression plasmid, strain E. 
Several different pairs of EGFP-expression systems 
were combined to produce five additional ‘double-
recombinant’ strains. The antigen expression levels, 
and immunogenic properties of these single and 
double-recombinant strains were systematically 
investigated in mice.
 Based on the study of Salmonella-EGFP strains, 
three Salmonella-AIV strains were constructed: 
one chromosome-based Salmonella AIV strain 
(YBS010), in which multiple antigens of AIV (HA, 
NA, M2, NP) were inserted into the chromosome 
of Salmonella typhi Ty21a using an optimised 
recombinant method; one high-copy-plasmid-
cytoplasmic-expression strain (C-HAOP); and one 
high-copy-plasmid-outer-membrane expression 
strain (O-HAOP). Their immune responses in mice 
and chicken were investigated via ELISA, ELISpot, 
haemagglutinin inhibition (HAI), and H5N1 virus 
challenge.
Results
Six ‘single-recombinant’ and five ‘double-
recombinant’ Salmonella-EGFP strains were 
constructed to compare the immunogenic 
properties of various recombinant Salmonella 
strains. Maintaining high antigen expression levels 
was important for eliciting a strong B cell response. 
If the antigen (such as EGFP) is soluble and easily 
expressed in Salmonella, a low-copy plasmid-based 
strategy should be used, as it can provoke both 
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strong B cell and T cell responses. Furthermore, 
the stability of antigen expression is important 
for eliciting a strong T cell response against the 
recombinant vaccine strains. If a T cell response is 
preferred, a eukaryotic plasmid, or chromosome-
based expression strategy may achieve better results. 
Nonetheless, a combination of two expression 
strategies did not enhance the immune response. 
 Based on the study of Salmonella-EGFP 
strains, three live recombinant Salmonella oral 
vaccine candidates against AIV were constructed. A 
chromosome-based Salmonella AIV strain YBS010 
was first constructed. In the YBS010 strain, four 
antigen genes of AIV (HA, NA, M2, NP) were cloned 
and recombined into the chromosome of Salmonella 
typhi Ty21a strain using the novel recombinant 
method,6 and their expression was confirmed. 
Immunogenicity assays in mice (ELISA and 
ELISpot) indicated that they were not strong enough 
to generate protective B cell and T cell responses 
against the AIV (data not shown). According to 
the study of Salmonella-EGFP strains, a weak B 
cell response may be due to the low expression 
level of four antigens expressed by the single copy 
chromosome-based expression cassettes. A low 
T cell response was probably due to codon bias or 
inability to express soluble, correctly folded epitopes 
in YBS010.
 Then, two Salmonella-HA strains were 
constructed including one cytoplasmic expression 
strain (C-HAOP) and one outer-membrane 
expression strain (O-HAOP). Both strains are 
based on high-copy plasmids. Previous studies have 
reported that many antigens from eukaryotic viruses 
(such as the HA protein from H5N1) cannot be readily 
expressed in a soluble form within the cytoplasm 
of Salmonella. Thus, the codons of the HA epitope 
were first optimised according to the Salmonella 
codon bias. Nonetheless, codon optimisation did not 
solve the insolubility problem of the HA epitope in 
C-HAOP strain. This may account for failure of the 
following immune test in mice models. 
 According to our in vivo immune response 
assays, no detectable B cell or T cell responses 
were observed when mice were immunised with 
the C-HAOP strain (Table 1). For O-HAOP strain, 
the use of the Lpp-ompA system resulted in the 
successful export of the HA epitope to the outer 
membrane fraction. Results from ELISA, HAI, 
and ELISpot assays in mice indicated that this 
strain was capable of inducing better HA-specific 
B cell and T cell responses than the corresponding 
C-HAOP strain (Tables 1 to 3) that expresses the HA 
antigen in the cytoplasm. The use of the Lpp-OmpA 
system probably helped the HA protein fold into a 
soluble conformation, or resulted in the export of 
increased amounts of HA protein, causing notable 
enhancements in immunogenicity. Although the 
TABLE 1.  HA-specific IgG responses in infected mouse sera
TABLE 2.  Haemagglutinin inhibition (HAI) in infected mouse 
sera
Group No. responding / total No. (mean IgG titre)
Day 7 Day 28 Day 42
O-HAOP 1/10 (100) 3/10 (160) 3/10 (250)
C-HAOP 0/6 (0) 0/6 (0) 0/6 (0)
Group No. responding / total No. (mean titre)
Non-infection HO O-HAOP
O-HAOP 1/10 (100) 3/10 (160) 3/10 (250)
TABLE 3.  IFN-γ responses to recombinant SL7207-HA strains
Group Mean ratio (total mice No.)
HO 0.69 (n=5)
O-HAOP 2.56 (n=5)
C-HAOP 0.91 (n=5)
FIG.  Challenge result of mice infected with C-HAOP and O-HAOP strains using 
the dose of 50 LD50 H5N1 virus 
Mice immunised with the HO strain and non-infected mice were negative controls. 
Mice were observed for sick and survival rates for 21 days. The survival rate per day 
after challenge was the challenge result
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TABLE 4.  HA-specific IgY responses in infected chicken sera
Group No. responding / total no. (mean titre)
HO (1011) O-HAOP (1010) O-HAOP (1011)
Titre 0/4 (0) 0/4 (0) 0/4 (0)
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O-HAOP strain increased the immune response 
in mice, this strain was still not strong enough to 
protect mice from the H5N1 virus challenge (Fig). 
In the chicken humoral immune response study, 
O-HAOP strain could not induce the significant 
HA-specific IgY response (Table 4). This may be 
due to the drawback of outer-membrane expression 
system in Salmonella-EGFP strains. 
 The total amounts of antigen synthesised and 
exported to the outer membrane were low, and the 
high-copy plasmid was not as stable as low-copy 
plasmid or chromosome-based expression cassette. 
Therefore, optimisation of this vaccine candidate is 
needed. Recombinant flagella can remain at the site 
of administration for many hours and are efficiently 
presented to the immune system to provoke the 
production of specific antibodies against the 
inserted foreign antigen and protection against 
challenge infection. The optimised recombinant 
technology can be used to integrate multiple copies 
of HA epitope into the Salmonella flagellin gene 
(fliC) to create a chromosome-based SL7207-fliC-
HA strain. Chromosome-based expression cassette 
was more stable than plasmid-based expression 
cassette, which could help the flagellin-HA gene 
express constitutively. Flagellin-fused HA repeats 
would solve the insolubility problem of HA in the 
C-HAOP strain (cytoplasmatically expressed HA 
strain) and result in an increased expression level 
of HA compared with O-HAOP (outer membrane 
fused HA). The live, chromosome-based SL7207-
fliC-HA strain could be orally administered to mice 
and chicken to test its immunogenic efficiency as 
described before.
Discussion
A method to integrate and express multiple H5N1 
antigen genes in Salmonella was developed. It can 
serve as a general approach for future construction 
and optimisation of Salmonella recombinant 
strains. 
 The construction strategies of recombinant 
Salmonella vaccine strains for various needs and 
different forms of antigens were proposed. Such 
information can help guide the development of live 
recombinant Salmonella oral vaccines against AIV 
as well as other pathogens. If an epidemic arises, 
relevant vaccines can be synthesised in a very short 
time. 
 Using the optimised recombinant method, 
several live Salmonella vaccine candidates against 
AIV were tested in animal models. These candidate 
vaccines stimulated a specific immune response 
against H5N1, although the efficacy was too low 
to protect the animals. Further optimisation of the 
vaccine candidates is necessary for rapid production 
during an epidemic. If AIV drifts or shifts to other 
subtypes, relevant vaccines can also be produced 
quickly. 
 As the vaccine can be administrated orally, it 
is more convenient for mass administration in the 
poultry industry and avoids the use of hypodermic 
needles. The Salmonella-based vaccines also have 
the advantage of being easy to manufacture, as 
bacterial cultures need simple media and do not 
require special equipment. 
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